Ryvu Therapeutics SA (0RKT) Ratios
Ryvu Therapeutics SA Ratios
GB:0RKT's free cash flow for Q2 2026 was $-9.84M. For the 2026 fiscal year, GB:0RKT's free cash flow was decreased by $-219.00K and operating cash flow was $-9.62M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.26 | 2.52 | 3.99 | 8.21 | 2.88 |
| Quick Ratio | 2.24 | 2.51 | 3.96 | 8.17 | 2.83 |
| Cash Ratio | 0.97 | 1.48 | 0.83 | 2.27 | 2.30 |
| Solvency Ratio | -0.60 | -0.43 | -0.57 | -0.54 | -1.12 |
| Operating Cash Flow Ratio | -1.79 | -1.20 | -1.21 | 0.48 | -1.60 |
| Short-Term Operating Cash Flow Coverage | -1030.67 | -443.42 | -665.75 | 24.39 | -69.47 |
| Net Current Asset Value | $ -14.44M | $ 37.54M | $ 134.78M | $ 236.34M | $ 44.86M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.32 | 0.20 | 0.00 | 0.01 | 0.02 |
| Debt-to-Equity Ratio | 1.33 | 0.52 | 0.00 | 0.01 | 0.03 |
| Debt-to-Capital Ratio | 0.57 | 0.34 | 0.00 | 0.01 | 0.03 |
| Long-Term Debt-to-Capital Ratio | 0.57 | 0.34 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 4.17 | 2.63 | 1.55 | 1.38 | 1.42 |
| Debt Service Coverage Ratio | -12.66 | -23.69 | -361.80 | -35.55 | -51.82 |
| Interest Coverage Ratio | -13.88 | -32.06 | -1040.70 | -72.01 | -234.80 |
| Debt to Market Cap | 0.11 | 0.08 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 3.48 | 3.43 | 0.04 | 0.21 | 0.30 |
| Net Debt to EBITDA | -0.11 | 0.87 | 0.70 | 1.52 | 1.19 |
| Profitability Margins | |||||
| Gross Profit Margin | -187.99% | 74.89% | 62.54% | 55.14% | -22.69% |
| EBIT Margin | -196.22% | -137.66% | -196.36% | -201.28% | -701.92% |
| EBITDA Margin | -181.05% | -124.20% | -172.95% | -168.04% | -589.64% |
| Operating Profit Margin | -196.22% | -156.60% | -215.42% | -202.10% | -927.76% |
| Pretax Profit Margin | -162.47% | -142.54% | -196.57% | -204.09% | -705.87% |
| Net Profit Margin | -162.61% | -142.92% | -196.57% | -215.91% | -706.91% |
| Continuous Operations Profit Margin | -162.61% | -142.92% | -196.57% | -215.91% | -706.91% |
| Net Income Per EBT | 100.09% | 100.27% | 100.00% | 105.79% | 100.15% |
| EBT Per EBIT | 82.80% | 91.02% | 91.25% | 100.99% | 76.08% |
| Return on Assets (ROA) | -45.10% | -29.42% | -22.85% | -17.64% | -34.56% |
| Return on Equity (ROE) | -188.04% | -77.45% | -35.48% | -24.40% | -49.02% |
| Return on Capital Employed (ROCE) | -75.01% | -45.08% | -30.27% | -18.23% | -53.88% |
| Return on Invested Capital (ROIC) | -74.78% | -44.95% | -30.22% | -18.15% | -53.12% |
| Return on Tangible Assets | -46.35% | -30.06% | -23.21% | -17.80% | -35.03% |
| Earnings Yield | -16.16% | -12.52% | -7.12% | -9.28% | -7.06% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.10 | 3.73 | 5.10 | 7.68 | 0.95 |
| Payables Turnover | 11.05 | 0.63 | 0.76 | 1.38 | 1.17 |
| Inventory Turnover | 134.30 | 16.18 | 8.29 | 9.90 | 7.01 |
| Fixed Asset Turnover | 0.89 | 1.07 | 0.60 | 0.47 | 0.12 |
| Asset Turnover | 0.28 | 0.21 | 0.12 | 0.08 | 0.05 |
| Working Capital Turnover Ratio | 0.51 | 0.42 | 0.18 | 0.20 | 0.11 |
| Cash Conversion Cycle | 87.53 | -460.21 | -365.59 | -179.38 | 124.28 |
| Days of Sales Outstanding | 117.85 | 97.92 | 71.56 | 47.51 | 383.10 |
| Days of Inventory Outstanding | 2.72 | 22.56 | 44.04 | 36.89 | 52.04 |
| Days of Payables Outstanding | 33.04 | 580.68 | 481.19 | 263.78 | 310.85 |
| Operating Cycle | 120.57 | 120.47 | 115.60 | 84.40 | 435.13 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -4.77 | -5.60 | -3.69 | 1.16 | -3.15 |
| Free Cash Flow Per Share | -5.09 | -5.86 | -3.85 | 0.66 | -3.81 |
| Dividend Paid and CapEx Coverage Ratio | -14.76 | -21.93 | -9.86 | 2.30 | -4.83 |
| Capital Expenditure Coverage Ratio | -14.76 | -21.93 | -9.86 | 2.30 | -4.83 |
| Operating Cash Flow Coverage Ratio | -1.54 | -1.71 | -93.32 | 7.70 | -11.41 |
| Operating Cash Flow to Sales Ratio | -1.77 | -1.66 | -1.80 | 0.55 | -5.17 |
| Free Cash Flow Yield | -18.79% | -15.21% | -6.81% | 1.33% | -6.24% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -6.19 | -7.99 | -14.05 | -10.78 | -14.16 |
| Price-to-Sales (P/S) Ratio | 10.06 | 11.42 | 27.61 | 23.27 | 100.09 |
| Price-to-Book (P/B) Ratio | 11.64 | 6.19 | 4.98 | 2.63 | 6.94 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -5.32 | -6.57 | -14.68 | 75.05 | -16.03 |
| Price-to-Operating Cash Flow Ratio | -5.68 | -6.87 | -15.30 | 42.36 | -19.35 |
| Price-to-Earnings Growth (PEG) Ratio | 0.68 | -0.40 | 1.17 | -1.79 | -0.11 |
| Enterprise Value Multiple | -5.67 | -8.32 | -15.26 | -12.33 | -15.79 |
| Enterprise Value | 638.67M | 805.57M | 1.24B | 803.83M | 1.04B |
| EV to EBITDA | -5.67 | -8.32 | -15.26 | -12.33 | -15.79 |
| EV to Sales | 10.26 | 10.33 | 26.39 | 20.72 | 93.11 |
| EV to Free Cash Flow | -5.42 | -5.95 | -14.04 | 66.81 | -14.91 |
| EV to Operating Cash Flow | -5.79 | -6.22 | -14.63 | 37.70 | -18.00 |
| Tangible Book Value Per Share | 2.80 | 5.87 | 11.06 | 18.50 | 9.06 |
| Shareholders’ Equity Per Share | 2.33 | 6.22 | 11.34 | 18.73 | 8.79 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | 0.00 | -0.06 | -0.00 |
| Revenue Per Share | 2.69 | 3.37 | 2.05 | 2.12 | 0.61 |
| Net Income Per Share | -4.38 | -4.82 | -4.02 | -4.57 | -4.31 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.06 | 1.00 |
| Interest Burden | 0.83 | 1.04 | 1.00 | 1.01 | 1.01 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.67 | 1.34 |
| SG&A to Revenue | 0.06 | 0.06 | 0.00 | 0.14 | 0.39 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.57 | 2.06 |
| Income Quality | 1.09 | 1.16 | 0.92 | -0.25 | 0.75 |
Currency in PLN
